8-K: Oragenics Faces NYSE Delisting Warning Amid Clinical Trial Progress

Oragenics, Inc. has received a delisting notice from NYSE American due to non-compliance with continued listing standards, despite advancing its Phase IIa clinical trial for ONP-002.

Summary

• Oragenics, Inc. received a notification from NYSE American on August 26, 2026, stating it is no longer in compliance with continued listing standards.
• The company failed to meet stockholders' equity requirements, with $3.7 million reported on June 30, 2026, and has incurred net losses for the past five fiscal years.
• Oragenics must submit a plan of compliance by September 25, 2026, to regain compliance by February 25, 2028.
• The company's shares will continue to trade under the OGEN symbol but with a .BC designation indicating below compliance status.
• Despite the listing issue, Oragenics is progressing with its Phase IIa clinical trial for ONP-002 (a concussion treatment), having dosed nine participants across three active sites in Australia.
• The company is also reviewing feedback from the FDA regarding its Type B meeting request and aims to submit an Investigational New Drug (IND) application by the end of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the NYSE American delisting notice, despite ongoing clinical progress.

Positives

• Continued progress in the Phase IIa clinical trial for ONP-002, with nine participants dosed across three active sites in Australia.
• Received constructive feedback from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request.
• Focused on submitting an Investigational New Drug (IND) application by the end of 2026.

Negatives

• Received a deficiency letter from NYSE American LLC on August 26, 2026, indicating non-compliance with continued listing standards.
• Stockholders' equity of $3.7 million as of June 30, 2026, falls below the $4 million and $6 million thresholds required by NYSE American.
• Reported net losses for the last five fiscal years, contributing to the non-compliance.
• Shares will trade with a '.BC' designation, signifying below compliance status.
• Potential delisting if a compliance plan is not submitted, accepted, or if compliance is not achieved by February 25, 2028.

Risks

• Risk of delisting from NYSE American if a compliance plan is not submitted, accepted, or if compliance is not achieved by February 25, 2028.
• Potential reduction in liquidity and market price of common stock if delisted.
• Reduced investor willingness to hold or acquire common stock, impacting the ability to raise equity financing.
• Limited ability to use registration statements to offer and sell freely tradable securities, hindering access to public capital markets.
• Impaired ability to provide equity incentives to employees.
• Uncertainty regarding the successful submission and acceptance of the plan of compliance.
• Uncertainty regarding the ability to undertake transactions to achieve compliance with NYSE American requirements.

Future Outlook

The company is focused on submitting a plan of compliance to NYSE American by September 25, 2026, to regain compliance with listing standards by February 25, 2028. Concurrently, it aims to submit an IND application by the end of 2026 and continue its Phase IIa trial enrollment and dosing.

Management Comments

• Were encouraged by the pace of enrollment in Australia and by the FDAs engagement on our Type B package.
• The Company believes its recent progress including a third active Australian site, nine participants dosed, and constructive engagement with the FDA reflects continued momentum toward its year-end goals.

Industry Context

StockSavvy.ai notes that delisting warnings are a significant concern for small-cap biopharmaceutical companies, often signaling financial distress or a need for strategic restructuring. However, continued clinical progress and constructive regulatory engagement can sometimes mitigate these concerns if a viable path to compliance is demonstrated.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry standards for clinical trial enrollment or regulatory submission timelines.
• The NYSE American listing standards themselves represent an industry benchmark for financial health and operational stability for listed companies.

Stakeholder Impact

• Shareholders: Potential reduction in stock liquidity and market price, reduced investor base, and difficulty in raising equity financing.
• Employees: Impaired ability to provide equity incentives.
• Creditors: Potential concerns about the company's financial stability and ability to meet obligations if delisted and unable to access capital markets.

Next Steps

• Submit a plan of compliance to NYSE American by September 25, 2026.
• Continue Phase IIa enrollment and dosing in Australia.
• Advance U.S. IND submission by the end of 2026.
• Build out broader CNS pipeline.

Key Dates

Recommendation

The company is facing a significant risk of delisting, which is a strong negative. However, it is also making clinical progress and engaging with the FDA. A 'hold' recommendation reflects the uncertainty; investors should monitor the submission and acceptance of the compliance plan and the progress of the clinical trials.

Keywords

delisting, NYSE American, listing standards, compliance plan, stockholders equity, net losses, clinical trial, IND application